(Total Views: 530)
Posted On: 08/28/2019 5:40:31 AM
Post# of 156569
Is Dr. Sacha looking at this? "anti-drug antibody (ADA) responses restricted mAb delivery", of interest is that leronlimab doesn't produce an anti-drug antibody response.
https://www.ncbi.nlm.nih.gov/pubmed/30850342
Quote:
Long-term delivery of anti-HIV monoclonal antibodies (mAbs) using adeno-associated virus (AAV) vectors holds promise for the prevention and treatment of HIV infection. We describe a therapy trial in which four rhesus monkeys were infected with SHIV-AD8 for 86 weeks before receiving the AAV-encoded mAbs 3BNC117, 10-1074, and 10E8. Although anti-drug antibody (ADA) responses restricted mAb delivery, one monkey successfully maintained 50-150 μg/mL of 3BNC117 and 10-1074 for over 2 years. Delivery of these two mAbs to this monkey resulted in an abrupt decline in plasma viremia, which remained undetectable for 38 successive measurements over 3 years. We generated two more examples of virologic suppression using AAV delivery of a cocktail of four mAbs in a 12-monkey study. Our results provide proof of concept for AAV-delivered mAbs to produce a "functional cure." However, they also serve as a warning that ADAs may be a problem for practical application of this approach in humans.
https://www.ncbi.nlm.nih.gov/pubmed/30850342
(1)
(0)
